Johnson & Johnson Hike 2021 Profit Forecast as COVID-19 Vaccine Sales Grow

Sales of the cancer treatment Darzalex helped Johnson & Johnson deliver better-than-expected third-quarter earnings, while COVID-19 fueled vaccine revenue and had more customers reaching for Tylenol. The world’s biggest maker of health care products hiked its 2021 earnings forecast after saying Tuesday that net income climbed 3% to $3.67 billion in the recently completed quarter. … Read more